復星醫藥(02196.HK)控股子公司獲藥品臨牀試驗批準
格隆匯4月7日丨復星醫藥(02196.HK)公告,上海復星醫藥(集團)股份有限公司(以下簡稱“公司”)控股子公司復星醫藥(徐州)有限公司於近日收到國家藥品監督管理局關於同意CMC-2310口溶膜(以下簡稱“CMC-2310”)用於成人及13歲以上兒童患者的精神分裂症治療開展臨牀試驗的批準。
CMC-2310爲集團(即公司及控股子公司/單位,下同)自主研發的化學藥品,擬用於成人及13歲以上兒童患者的精神分裂症治療。截至2025年3月,集團現階段針對CMC-2310的累計研發投入約爲人民幣725萬元(未經審計)。
同活性成分的藥物系2024年於中國境內(不包括港澳臺地區)獲批上市。截至本公告日期(即2025年4月7日),暫未查詢到銷售統計數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.